BCRX vs. SPY
Compare and contrast key facts about BioCryst Pharmaceuticals, Inc. (BCRX) and SPDR S&P 500 ETF (SPY).
SPY is a passively managed fund by State Street that tracks the performance of the S&P 500 Index. It was launched on Jan 22, 1993.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BCRX or SPY.
Correlation
The correlation between BCRX and SPY is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
BCRX vs. SPY - Performance Comparison
Key characteristics
BCRX:
1.02
SPY:
1.88
BCRX:
1.82
SPY:
2.53
BCRX:
1.21
SPY:
1.35
BCRX:
0.67
SPY:
2.83
BCRX:
5.02
SPY:
11.74
BCRX:
11.68%
SPY:
2.02%
BCRX:
57.27%
SPY:
12.64%
BCRX:
-97.74%
SPY:
-55.19%
BCRX:
-71.65%
SPY:
-0.42%
Returns By Period
In the year-to-date period, BCRX achieves a 24.87% return, which is significantly higher than SPY's 4.15% return. Over the past 10 years, BCRX has underperformed SPY with an annualized return of -1.12%, while SPY has yielded a comparatively higher 13.18% annualized return.
BCRX
24.87%
23.39%
18.41%
66.19%
29.89%
-1.12%
SPY
4.15%
1.22%
10.44%
24.34%
14.62%
13.18%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
BCRX vs. SPY — Risk-Adjusted Performance Rank
BCRX
SPY
BCRX vs. SPY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for BioCryst Pharmaceuticals, Inc. (BCRX) and SPDR S&P 500 ETF (SPY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
BCRX vs. SPY - Dividend Comparison
BCRX has not paid dividends to shareholders, while SPY's dividend yield for the trailing twelve months is around 1.16%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BCRX BioCryst Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
SPY SPDR S&P 500 ETF | 1.16% | 1.21% | 1.40% | 1.65% | 1.20% | 1.52% | 1.75% | 2.04% | 1.80% | 2.03% | 2.06% | 1.87% |
Drawdowns
BCRX vs. SPY - Drawdown Comparison
The maximum BCRX drawdown since its inception was -97.74%, which is greater than SPY's maximum drawdown of -55.19%. Use the drawdown chart below to compare losses from any high point for BCRX and SPY. For additional features, visit the drawdowns tool.
Volatility
BCRX vs. SPY - Volatility Comparison
BioCryst Pharmaceuticals, Inc. (BCRX) has a higher volatility of 12.21% compared to SPDR S&P 500 ETF (SPY) at 2.93%. This indicates that BCRX's price experiences larger fluctuations and is considered to be riskier than SPY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.